Abstract
Cardiovascular disease continues to lead as one of the greatest contributors to mortality [1]. Cardiac sarcoidosis is a lesser known but highly lethal clinical condition that has been increasing in incidence and prevalence globally [1]. Within the radiologic modalities, both cardiac magnetic resonance imaging (MR) and positron emission tomography-computed tomography (PET-CT) have emerged as ideal imaging modalities used in evaluating and assisting with treatment considerations for cardiac sarcoidosis. MR and PET-CT are complementary in regards to imaging capabilities but certain patient population considerations lend themselves to favoring PET-CT over MR, In particular, although an increasing number of implanted cardiac defibrillators (ICDs) are MR-compatible, many patients do not have MR-compliant devices and are unable to have MR for sarcoidosis evaluation due to the dangers inherent to the MR’s magnetic field and the ferromagnetic properties of ICDs. For patient safety, cardiac PET-CT may be the only effective imaging option available.
Reference7 articles.
1. 1. Bateman, Thomas. Cardiac sarcoidosis: An important niche for PET, but a journey just begun. J.of Nucl Cardiol. 2017; 24 :425–428.
2. 2. Heller, Gary. Nuclear Cardiology: Practical Applications, Third Edition. McGraw-Hill. 2017
3. 3. Hulten, E. Saira Aslam, Michael Osborne, Siddique Abbasi, Marcio Sommer Bittencourt, and Ron Blankstein. Cardiac sarcoidosis—state of the art review. Cardiovasc Diagn Ther. 2016; 6:50–63.
4. 4. Osborne et al Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation. J. Nucl Cardiol. 2017; 24: 86-99.
5. 5. Schindler Thomas H and Solnes, Lilja. Role of PET/CT for the Identification of Cardiac Sarcoidosis. Annals of Nuclear Cardiology 2015; 179-86.